Blocking CD47/SIRPα interaction could induce phagocytosis [19, 25, 27] and enable DCs to cross-present tumor antigens through MHC class I molecules, which further activates CD8+ T cells that are specific for tumor antigens [28, 29]. The gene discussed is CD8A; the disease is neoplasm.